RANDOMIZED CONTROLLED STUDY COMPARING AEZS 108 WITH DOXORUBICIN AS SECOND LINE THERAPY FOR LOCALLY ADVANCED, RECURRENT OR METASTATIC ENDOMETRIAL CANCER.
- Registry ID
- AEZS-108-050
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- AETERNA ZENTARIS GMBH
- Start date
- 2014-01-27
- Completion date
- 2017-02-02
- Last update
- 2013-09-27
Conditions
- METASTATIC ENDOMETRIAL CANCER
- ADENOCARCINOMA
Related clinical trials
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF PUXITATUG
SAMROTECAN (AZD8205) MONOTHERAPY VERSUS PHYSICIAN¿S CHOICE OF CHEMOTHERAPY IN
PARTICIPANTS WITH B7-H4-SELECTED ADVANCED/METASTATIC ENDOMETRIAL CANCER WHO
PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND ANTI-PD-1/ANTI-PD-L1
THERAPY (BLUESTAR-ENDOMETRIAL01)
- A PHASE III MULTI-CENTER, OPEN-LABEL, SPONSOR-BLINDED, RANDOMIZED STUDY OF
AZD0901 MONOTHERAPY COMPARED WITH INVESTIGATOR¿S CHOICE OF THERAPY IN
SECOND- OR LATER-LINE ADULT PARTICIPANTS WITH ADVANCED/METASTATIC GASTRIC OR
GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING CLAUDIN18.2
- A RANDOMIZED PHASE 2 STUDY OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB IN ADVANCED, RECURRENT METASTATIC ENDOMETRIAL CANCER
- PHASE II TRIAL OF PERIOPERATIVE PD-L1 INHIBITION WITH AVELUMAB AND DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOR RESECTABLE LOCALLY ADVANCED ESOPHAGO-GASTRIC ADENOCARINOMA
- "A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE."
View on source registry